AGIO241220P15000
- 0.00
- 0.000.00%
Agios Pharmaceuticals Newsroom
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Agios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $53
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript Summary
Agios Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.
Agios Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Agios Pharmaceuticals | 8-K: Agios Reports Business Highlights and Third Quarter 2024 Financial Results
Agios Pharmaceuticals GAAP EPS of $16.22 Beats by $7.53, Revenue of $8.96M Misses by $0.54M
Agios Pharmaceuticals: Q3 Earnings Snapshot
Agios Expects Cash And Equivalents, Together With Anticipated Product Revenue And Interest Income, To Provide Financial Independence To Prepare For Potential PYRUKYND Launches, Advance Existing Programs, And Expand Pipeline
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q3 Revenue $9.0M
Agios Reports Business Highlights and Third Quarter 2024 Financial Results